Sienna Biopharmaceuticals acquires Creabilis

USA-based Sienna Biopharmaceuticals has acquired privately-held, UK-headquartered  Creabilis, a company focused on developing first-in-class topical treatments for common inflammatory skin conditions, including psoriasis, atopic dermatitis and pruritus (itch).

Under the terms of the agreement, Sienna will make an undisclosed upfront payment in cash and stock, as well as additional payments contingent upon achieving specific regulatory and commercial milestones, which could exceed $150 million in aggregate. Additional terms were not disclosed.

Sienna has acquired first-in-class late-stage and patented clinical candidates, including: